国家医保局等两部门：鼓励商业健康保险扩大创新药投资规模 培育支持创新药的耐心资本

Group 1 - The core viewpoint of the news is the issuance of measures to support the high-quality development of innovative drugs by the National Medical Insurance Administration and the National Health Commission, emphasizing the use of medical insurance data for drug research and development [1][2] - The measures encourage the integration of medical, insurance, and pharmaceutical data to enhance the efficiency of innovative drug development, allowing for better identification of research directions and development pipelines [1] - There is a focus on encouraging commercial health insurance to increase investment in innovative drugs through various means, including investment funds, to provide stable long-term capital for drug development [1] Group 2 - The measures outline the need to reasonably determine the medical insurance payment standards for innovative drugs, utilizing pharmacoeconomics and health technology assessments to align with China's national conditions and market status [2] - The approach includes negotiations between medical insurance departments and innovative drug companies to establish payment standards that reflect the clinical value of the drugs, while also considering factors like market competition and research investment [2] - The measures allow for adjustments in payment standards through negotiations in cases where innovative drugs exceed sales expectations or gain new indications, ensuring stability for companies [2]